# SCRIMED Global Enterprise Command Brief Status: global-enterprise-command-active-no-production-authority Updated: 2026-07-09 Average region readiness: 79 Region commands: 9 Sales playbooks: 7 Interoperability lanes: 10 Communication lanes: 4 ## Boundary SCRIMED Global Enterprise Command coordinates international viability, sales readiness, localization, interoperability, communication, and partner-readiness for synthetic evaluations and enterprise diligence. It is not legal advice, tax advice, regional regulatory approval, public-sector procurement approval, GDPR compliance assurance, HIPAA certification, SOC 2 certification, FDA clearance, NHS approval, production deployment approval, live PHI authority, live clinical care authority, payer submission authority, EHR writeback authority, reseller authorization, revenue guarantee, or customer go-live approval. This brief supports international diligence, localization, partner qualification, and no-PHI enterprise evaluation only. It does not authorize live PHI, production deployment, clinical care, diagnosis, treatment, prescribing, payer submission, EHR writeback, regional legal approval, certification, public-sector procurement approval, reseller authority, revenue guarantees, or customer go-live. ## Scorecards - International draw: 79. Evidence: 9 region commands and 7 buyer playbooks are mapped to proof routes. Risk: Regional counsel, procurement, privacy, and public-sector authority are still external-review gates. Next: Package the top launch and strategic regions into localized no-PHI outreach packets. - Global interoperability: 76. Evidence: 13 standards and 3 active controls are available for synthetic conformance work. Risk: Live connectors, profile selection, licensing, regional exchange participation, and writeback remain blocked. Next: Attach regional interoperability lanes to deployment profiles and buyer diligence packets. - Global communication: 92. Evidence: 9 templates, 6 calendar packets, and 32 approval gates support human-reviewed outreach. Risk: External communications, translations, partner claims, pricing, legal language, and clinical statements require review. Next: Use the communication lanes for every regional buyer, partner, investor, and public-sector conversation. - Global assurance: 71. Evidence: 6 approval tracks, 5 gates, and 5 regional packs are tracked. Risk: No certification, regulatory approval, public-sector procurement approval, or clinical validation claim is authorized. Next: Create evidence-room packets for the regions with the strongest commercial pull. ## Regional Commands - United States (launch-ready-for-synthetic-outreach, readiness 85): Prepare a localized no-PHI executive packet, map regional authority owners, and route any production data, legal, procurement, or clinical request to qualified review. Retained gates: signed enterprise scope, BAA/DPA where applicable, security review, clinical governance review, production connector approval - UAE (strategic-partner-review, readiness 79): Prepare a localized no-PHI executive packet, map regional authority owners, and route any production data, legal, procurement, or clinical request to qualified review. Retained gates: regional counsel review, hosting and residency approval, public-sector procurement process, qualified local implementation partner, translation and claims review - Saudi Arabia (strategic-partner-review, readiness 79): Prepare a localized no-PHI executive packet, map regional authority owners, and route any production data, legal, procurement, or clinical request to qualified review. Retained gates: regional counsel review, government procurement authority, data-residency approval, cybersecurity review, partner authority validation - Kuwait (strategic-partner-review, readiness 79): Prepare a localized no-PHI executive packet, map regional authority owners, and route any production data, legal, procurement, or clinical request to qualified review. Retained gates: qualified local partner, regional counsel review, buyer procurement process, data residency decision, customer go-live approval - Nigeria (launch-ready-for-synthetic-outreach, readiness 85): Prepare a localized no-PHI executive packet, map regional authority owners, and route any production data, legal, procurement, or clinical request to qualified review. Retained gates: local privacy review, public-sector authority where applicable, customer data-processing agreement, clinical governance reviewer, production support model - Kenya (strategic-partner-review, readiness 79): Prepare a localized no-PHI executive packet, map regional authority owners, and route any production data, legal, procurement, or clinical request to qualified review. Retained gates: local counsel review, partner authority validation, data-sharing approval, clinical governance review, production incident-response plan - Rwanda (strategic-partner-review, readiness 79): Prepare a localized no-PHI executive packet, map regional authority owners, and route any production data, legal, procurement, or clinical request to qualified review. Retained gates: public-sector procurement review, local counsel review, implementation partner qualification, data-residency decision, official approval before public naming - Ghana (strategic-partner-review, readiness 79): Prepare a localized no-PHI executive packet, map regional authority owners, and route any production data, legal, procurement, or clinical request to qualified review. Retained gates: local privacy review, clinical governance reviewer, production support owner, customer approval, partner authority validation - European Union and United Kingdom (watchlist-requires-localization, readiness 69): Prepare a localized no-PHI executive packet, map regional authority owners, and route any production data, legal, procurement, or clinical request to qualified review. Retained gates: regional counsel review, DPA and transfer assessment, clinical safety classification, AI governance review, country-level localization approval ## Sales Playbooks - Provider and health-system executives: Workflow Intelligence Assessment -> Synthetic Pilot Evaluation -> Protected Enterprise Pilot. Gate: Founder or qualified revenue owner reviews regional claims, pricing, proof routes, and external communication before send. Next: Route to `/pilot` with synthetic-only workflow scope, then Sales Operations qualifies buyer, region, proof needs, and protected workspace fit. - Payers, plans, and revenue-cycle leaders: Synthetic Pilot Evaluation -> RCM and Prior Authorization Blueprint -> Protected Enterprise Pilot. Gate: Founder or qualified revenue owner reviews regional claims, pricing, proof routes, and external communication before send. Next: Start with a synthetic RCM workflow pack, then require finance, legal, policy, and security review before protected pilot expansion. - Government and public-sector healthcare leaders: Strategic Platform Partnership. Gate: Founder or qualified revenue owner reviews regional claims, pricing, proof routes, and external communication before send. Next: Founder-led executive briefing, regional counsel review, public-sector procurement mapping, synthetic evaluation, then protected deployment planning. - Life sciences, research networks, oncology programs, and trial operations: TrialCore Research Operations Synthetic Pilot. Gate: Founder or qualified revenue owner reviews regional claims, pricing, proof routes, and external communication before send. Next: Use synthetic criteria packs and trial operations demos before data-governance, ethics, and customer authorization review. - Employers and benefits leaders: Workflow Intelligence Assessment. Gate: Founder or qualified revenue owner reviews regional claims, pricing, proof routes, and external communication before send. Next: Start with no-member-data workflow assessment, then require plan, privacy, legal, and consent review before any protected pilot. - Global channel partners and healthcare implementers: Strategic Platform Partnership. Gate: Founder or qualified revenue owner reviews regional claims, pricing, proof routes, and external communication before send. Next: Qualify partner scope, region, authority, support model, and claims permissions before any co-selling or external announcement. - Investors, advisors, and board reviewers: Investor and Board Readiness Review. Gate: Founder or qualified revenue owner reviews regional claims, pricing, proof routes, and external communication before send. Next: Use Public Market Readiness and Global Reach briefs for diligence preparation while keeping financial and securities boundaries explicit. ## Interoperability Lanes - FHIR: HL7 Fast Healthcare Interoperability Resources (profile-selection-required): Use deployment-approved FHIR R4 or R4B profiles for current enterprise integrations; monitor R5 and require explicit version negotiation. Evidence: CapabilityStatement, StructureDefinition profiles, ImplementationGuide, synthetic validation fixtures - SMART: SMART App Launch (profile-selection-required): Use SMART App Launch profiles for approved user-facing FHIR applications with least-privilege scopes and tenant-aware authorization. Evidence: approved scopes, launch-context tests, token audience validation, revocation tests - USCDI: United States Core Data for Interoperability (profile-selection-required): Map synthetic extraction targets to USCDI data classes before SCRIMED represents health-record coverage for U.S. buyers. Evidence: data-class inventory, FHIR profile mapping, missing-field register, provenance and source attribution - TEFCA: Trusted Exchange Framework and Common Agreement (mapped-for-synthetic-evaluation): Treat nationwide exchange as a governance and participant-path readiness track, not a direct SCRIMED live-exchange claim. Evidence: participant authority, customer exchange pathway, privacy/security policy, audit and consent evidence - HL7 v2: HL7 Version 2 Messaging (profile-selection-required): Negotiate message versions, local profiles, segment requirements, acknowledgements, and replay behavior per source system. Evidence: message profile, sample messages, ACK/NACK behavior, dead-letter and replay tests - DICOM: Digital Imaging and Communications in Medicine (profile-selection-required): Use approved DICOM and DICOMweb services for imaging exchange, with a deployment-specific conformance statement and no diagnostic interpretation by the connector. Evidence: DICOM Part 2 conformance statement, transfer syntax tests, DICOMweb service tests, de-identification validation - X12: X12 Insurance and Administrative Transactions (license-or-partner-review-required): Select payer-approved transaction versions and implementation guides before eligibility, claim, remittance, status, or authorization exchange. Evidence: licensed implementation guide, trading-partner agreement, synthetic transaction tests, acknowledgement validation - CMS APIs: CMS Interoperability and Prior Authorization API Readiness (profile-selection-required): Prepare payer, provider, and prior-authorization workflows for API-based evidence packets while retaining payer/trading-partner approval and no-guarantee reimbursement boundaries. Evidence: payer API scope, synthetic prior-auth fixture, human RCM review, policy-source attribution, audit trail - C-CDA: Consolidated Clinical Document Architecture (profile-selection-required): Use deployment-approved C-CDA document templates when clinical document exchange is required alongside resource-level FHIR exchange. Evidence: template validation, document parser tests, source document retention, terminology validation - IHE: Integrating the Healthcare Enterprise Profiles (profile-selection-required): Select deployment-specific IHE profiles to constrain standards into testable cross-enterprise workflows. Evidence: selected integration profile, actor and transaction map, Connectathon-style tests, security profile validation ## Communication Lanes - regional executive email: Introduce SCRIMED as governed healthcare intelligence infrastructure using no-PHI proof routes. Review required: true. Next: Draft from /client-onboarding templates and queue founder or revenue-owner review. - bilingual executive briefing: Support Arabic/English and country-specific executive conversations for strategic regions. Review required: true. Next: Prepare a localized proof packet with region gates and no-production-authority language. - partner qualification workshop: Validate channel partner authority, implementation fit, data-residency assumptions, and procurement path. Review required: true. Next: Use /global-reach partner channels and /trust-center proof routes before any public relationship claim. - security and procurement review: Answer enterprise diligence questions with evidence routes, open gates, and owner assignments. Review required: true. Next: Route requests to /global-certification-readiness, /scrimed-cyber-defense, and /enterprise-healthcare-infrastructure. ## Blocked Claims - regional legal approval - public-sector procurement approval - GDPR compliance assurance - claiming HIPAA certification - claiming SOC 2 certification - claiming FDA clearance - claiming NHS approval - live PHI approved - production connector approved - autonomous clinical care - claiming payer submission authority - claiming EHR writeback authority - claiming customer go-live approval - revenue guarantee Next build step: Turn the highest-scoring global region commands into localized no-PHI proof packets with region counsel review, interoperability assumptions, human-reviewed communication templates, and protected partner qualification records.